Hot Income Companies To Buy For 2014

Getty Images By One in three Americans could be wasting $2,600 a year at the grocery store, a new survey by recipe kit company HelloFresh found.That's $50 per week thrown away on items that are either tossed out or never used. Married couples are more likely to walk away with unnecessary items in their cart, the survey found. But even most singles do: 12 percent of them said they never overspend, compared to 7 percent of married couples. Although the numbers are striking, Americans still spend a lower percentage of their annual income on food than any other country. A recent Bloomberg Businessweek chart shows the average consumer's food expenses fell from 16.8 percent of annual income in 1984 to 11.2 percent in 2011. Even so, $2,600 isn't something most people can afford to throw away. Here are a few ways to shave down some of your excess spending at the grocery store: 1. Shy away from brand names. The products with the grocery store's own label are often just as good and usually come for a cheaper price. 2. Buy ingredients, rather than prepared products. If you have time to make your own pasta salad at home, you can save money compared to buying the finished product at the store. 3. Purchase produce when it's in season. Apples cost the least during fall harvest season and berries are more of a bargain in the summer than the winter. 4. Don't shop on an empty stomach. You're more likely to overfill your cart in response to your stomach's rumblings. 5. Skip the bottled water. At a dollar per bottle, the costs add up fast, and you can always buy a filter for your tap water, which flows for a tiny fraction of the cost. 6. Make a list. It takes a few minutes of advance preparation, but it will save you from wandering aimlessly down the pasta aisle, debating possibilities for your Sunday night meal. 7. Learn to love bulk. Buying larger boxes of cereals and crackers can typically save you a few cents on per unit cost, and your snacks will stick around your cupboards for longer. More from Business Insider: Simple Household Tips That Will Save You Thousands Of Dollars Every Year 22 Products That Really Do Last A Lifetime

Hot Wireless Telecom Companies To Watch For 2015: World Wrestling Entertainment Inc.(WWE)

World Wrestling Entertainment, Inc., an integrated media and entertainment company, engages in the sports entertainment business. The company develops content centered around its talent, and presents at its live and televised events featuring World Wrestling Entertainment. It operates through four segments: Live and Televised Entertainment, Consumer Products, Digital Media, and WWE Studios. The Live and Televised Entertainment segment conducts live events; produces television shows; sells merchandise at its live events; provides sponsorships, such as various promotional vehicles, including Internet and print advertising, arena signage, on-air announcements, and pay-per-view sponsorships for advertisers; offers television rights; and markets and promotes the storylines associated with pay-per-view events. It also provides WWE Classics On Demand, a subscription video on demand service that offers classic television shows, pay-per-view events, specials, and original programmi ng. This segment distributes its programming in approximately 30 languages and in approximately 145 countries. Its merchandise consists of various WWE-branded products, such as T-shirts, caps, and other novelty items. The Consumer Products segment licenses and sells retail products, including toys, video games, home videos, apparel, and books; and publishes magazines comprising lifestyle publications with native language editions in the UK, Mexico, Greece, and Turkey. The Digital Media segment operates Web sites; provides advertising services; sells merchandise on its Web site at WWEShop Internet storefront; and offers broadband and mobile content. The WWE Studios segment is involved in the distribution of entertainment films. This segment focuses on creating a mix of filmed entertainment. The company was founded in 1980 and is based in Stamford, Connecticut.

Advisors' Opinion:

• [By Eric Volkman]

  World Wrestling Entertainment (NYSE: WWE  ) has elected to maintain its dividend. The company declared a quarterly distribution of $0.12 per share of both its class A and B common stock, to be paid on Sept. 25 to shareholders of record as of Sept. 13. That amount matches each of the company's previous distributions stretching back to June 2011. Before that, it paid out considerably more at $0.36 per share.

• [By Matt Egan]

  WWE (WWE) revealed plans on Thursday to slash 7% of its workforce in an effort to save cash.

  A WWE spokesman said the job cuts will impact all business units and locations. He said the pink slips will begin flying on Thursday.

Hot Income Companies To Buy For 2014: Gladstone Investment Corporation (GAIN)

Gladstone Investment Corporation specializes in buyouts and recapitalizations. It seeks to make debt and equity investments in small and mid-sized private businesses. The fund invests in junior subordinated loans, mezzanine debt, preferred stock, and warrants to purchase common stock of companies based in the the United States. It can also invest in senior secured loans and common stock. The fund prefers to invest between $3 million and $20 million. It invests individually as well as jointly with other buyout funds. The fund is treated as a business development company under the 1940 Act.

Advisors' Opinion:

• [By Monica Gerson]

  Gladstone Investment (NASDAQ: GAIN) is projected to post its Q4 earnings at $0.17 per share on revenue of $8.90 million.

  First Horizon National (NYSE: FHN) is expected to report its Q2 earnings at $0.17 per share on revenue of $286.98 million.

• [By Monica Wolfe]

  Gladstone Investment Corporation (GAIN)

  Over the past week two corporate executives made buys into Gladstone Investment Corporation. COO Terry Brubaker made three different buys over the past week and CEO David Gladstone made one.

Hot Income Companies To Buy For 2014: Roche Holding AG (RHHBY)

Roche Holding AG is a Switzerland-based pharmaceuticals and diagnostics company. The Company belongs to the Roche Group that operates through numerous subsidiaries and associated companies located around the world. The Company�� products and services cover every stage of the healthcare process, from identifying disease susceptibilities and testing for disease in at-risk populations to prevention, diagnosis, therapy and treatment monitoring. Roche operates through two divisions: Pharmaceuticals and Diagnostics. Within the Pharmaceuticals Division there are three sub-divisions: Roche Pharmaceuticals, Genentech and Chugai. The Company�� Diagnostics Division includes five sub-divisions: Applied Science, Diabetes Care, Molecular Diagnostics, Tissue Diagnosis and Professional Diagnostics. Its activities are structured into six geographical segments: North America; Asia-Pacific; Western Europe; Latin America; Central and Eastern Europe, Middle East and Africa (CEMAI), and Japan. In March 2009, the Company completed the acquisition of Genentech, Inc. In March 2010, the Company acquired assets from BioMicro Systems for all products associated with the Roche NimbleGen microarray workflow.

During the year ended December 31, 2008, the Company Pharmaceuticals Division marketing gained approvals for its rheumatoid arthritis medicine Actemra/RoActemra in Japan, Switzerland and the European Union. In 2008, the division initiated 12 new phase III projects in, including clinical trials of the compounds pertuzumab, for breast cancer; taspoglutide, for type two diabetes, and dalcetrapib, for cardiovascular risk reduction. As of December 31, 2008, the Pharmaceuticals Division filed 11 major new marketing applications and gained 13 major regulatory approvals. At the beginning of 2009, the division�� research and development pipeline comprised 120 clinical projects, including 62 new molecular entities (NMEs) and 58 additional indications. Forty NMEs are in phase I, 16 in phase II and six in phase III or f! iled for regulatory review.

In 2008, Roche Pharmaceuticals signed a total of 57 new agreements including seven product transactions and 43 research and technology collaborations. In May 2008, Roche acquired Piramed Limited, a UK company with therapeutic research programmes targeting the PI3-kinase pathway in oncology and inflammatory disease. In June 2008, signed licensing agreement with ThromboGenics and BioInvent for their jointly developed anticancer agent TB-403 (R7334). In September, 2008, the Company acquired Mirus Bio Corporation active in the field of ribonucleic acid interference (RNAi) delivery and completed the acquisition of ARIUS Research Inc., which has a antibody platform that identifies and selects antibodies based on their functional ability to affect disease. S Research Inc. In January 2009, Roche acquired Memory Pharmaceuticals, which develops drug candidates for the treatment of debilitating central nervous system disorders such as Alzheimer�� disease and schizophrenia.

Pharmaceuticals

Within Pharmaceuticals division, the Company is engaged in the provision of drugs the areas of oncology, anemia, cardiovascular diseases, central nervous system, infectious diseases, inflammatory and autoimmune diseases, metabolic disorders, cancer, transplantation and virology. The products offered by Roche�� Pharmaceuticals division include MabThera/Rituxan, Herceptin, Avastin, Tamiflu, CellCept, NeoRecormon, Epogin, Pegasys, Tarceva, Xeloda, Bonviva, Boniva, Lucentis, Tamiflu, Xolair, Valcyte, Cymevene, Xenical, Pulmozyme, Nutropin, Neutrogin, Rocephin, Activase, TNKase and Madopar. The products offered by the Pharmaceuticals division are sold in seven geographic regions: North America; Asia-Pacific; Western Europe; Latin America; Central and Eastern Europe, Middle East and Africa (CEMAI), and Japan.

Diagnostics

Roche�� Diagnostics Division is a supplier of in vitro diagnostics (IVDs). Its products are used to test body fluids a! nd tissue! samples to obtain information for the purpose of preventing, diagnosing, treating and monitoring disease. The Company has business areas five within the diagnostics division: Professional Diagnostics, Diabetes Care, Tissue Diagnostics, Molecular Diagnostics and Applied Science. Roche�� Diagnostics division provides IVD services, including centralized laboratory testing and point-of-care diagnostics to molecular diagnostics and diabetes self management. In addition, it supplies research tools to life scientists.

Roche Professional Diagnostics supplies instrument systems, tests, software and services. It provides point-of-care testing products to support clinical decision-making close to the patient, in doctors��offices, emergency rooms and other primary and specialty care settings. Twelve Serum Work Area assays were rolled out during the year ended December 31, 2008, across Europe and in other markets. New assays included the Elecsys anti-TSH receptor antibody assay for the diagnosis of Graves��disease the Elecsys anti-CCP antibody assay, a test to aid the diagnosis of rheumatoid arthritis, and the Roche Cystatin C clinical chemistry test for early detection of impaired kidney function, among others. Roche Diabetes Care�� products portfolio covers the entire diabetes self-management spectrum, from glucose monitoring to insulin delivery, as well as monitoring systems with integrated lancets and test strips software for storing and analyzing data. Roche Tissue Diagnostics develops and manufactures medical diagnostic instruments and reagent systems that provide automation technology for use in the diagnosis and prognosis of cancer and infectious disease. In 2008 Roche Tissue Diagnostics launched ofhe Bench- Mark Ultra, a system that performs immunohistochemistry and in situ hybridisation testing simultaneously on a single continuous and random access platform. Roche Molecular Diagnostics develops and commercializes diagnostic and blood screening platforms and tests based on Roche�� ! real-time! polymerase chain reaction (PCR) technology. Applied Science business area supplies a specific reagents and test kits for use in life sciences encompassing biology, biotechnology ,medical research, as well as disease areas like cancer and virology. Applied Science�� business area product portfolio includes such sequencing systems as LightCycler 480, LightCycler 480 II, GS FLX Titanium. In addition, Applied Science offers xCELLigence cell analyzer.

Advisors' Opinion:

• [By Sean Williams]

  Dendreon's likely partner
  While it's purely speculation on my part, I believe the most likely marketing partner would be one of Europe's premier cancer-fighting companies, Roche (NASDAQOTH: RHHBY  ) .

Hot Income Companies To Buy For 2014: Ancestry.com Inc.(ACOM)

Ancestry.com Inc. operates as an online family history resource for subscribers worldwide. The company?s subscribers use Web-based services and content collection to research their family histories, build their family trees, collaborate with other subscribers, upload their own records, and publish and share their stories. Its subscribers can search through its collection of various records that cover birth records, marriage and death records, census records, immigration documents, photographs, maps, military records, personal narratives, and newspapers. As of December 31, 2011, the company had 1.7 million paying subscribers. Ancestry.com Inc. was founded in 1983 and is headquartered in Provo, Utah.

Advisors' Opinion:

• [By CRWE]

  Ancestry.com Inc. (Nasdaq:ACOM) will release financial results for its third quarter 2012 on Wednesday, October 24, 2012 at approximately 2:00 p.m. MT (4:00 p.m. ET). Following the release, the Company will host a conference call with analysts and investors at 3:00 p.m. MT (5:00 p.m. ET).

Hot Income Companies To Buy For 2014: Maxygen Inc.(MAXY)

Maxygen, Inc., a biopharmaceutical company, focuses on developing improved versions of protein drugs in North America and Europe. The company utilizes its MolecularBreeding directed evolution technology platform, along with ancillary technologies, and protein modification expertise to pursue the creation of biosuperior proteins. It engages in the discovery, research, and development of MAXY-G34 product candidates for the treatment of chemotherapy-induced neutropenia. The company was founded in 1996 and is headquartered in Redwood, California.

Advisors' Opinion:

• [By Geoff Gannon]

  1. Steel Excel (SXCL)
  2. FormFactor (FORM)
  3. Imation (IMN)
  4. Tuesday Morning (TUES)
  5. Pacific Biosciences (PACB)
  6. Maxygen (MAXY)
  7. Westell (WSTL)
  8. Volt Information Sciences (VISI)
  9. Yasheng Group (YHGG)

Hot Income Companies To Buy For 2014: BIND Therapeutics Inc (BIND)

BIND Therapeutics, Inc., incorporated on May 19, 2006, is a clinical-stage nanomedicine platform company developing Accurins, its targeted and programmable therapeutics. Accurins are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Its drug candidate, BIND-014, is in Phase II clinical trials for non-small cell lung cancer, or NSCLC, and metastatic castrate-resistant prostate cancer (mCRPC).

Accurins represent the evolution of targeted therapies and nanomedicine. Accurins are polymeric nanoparticles that incorporate a therapeutic payload and are designed to have prolonged circulation within the bloodstream, enable targeting of the diseased tissue or cells, and provide for the controlled and timely release of the therapeutic payload. The four components include Targeting ligands, Stealth and protective layer, Controlled-release polymer matrix and Therapeutic payload. The Company focuses to use its medicinal nanoengineering platform to develop Accurins in several therapeutic areas, with an initial focus on the treatment of various types of cancer. In addition, the Company entered into collaboration agreements with several biopharmaceutical companies to develop and commercialize Accurins that are based on its collaborators��therapeutic payloads. The Company�� programs include BIND-014, solid tumor accurin and hematologic cancer accurin.

Advisors' Opinion:

• [By John Udovich]

  If you have not been watching the biotech sector lately, you should start paying attention as the sector along with small cap biotech stocks like Cell Therapeutics Inc (NASDAQ: CTIC), BIND Therapeutics Inc (NASDAQ: BIND) and TNI BioTech (OTCMKTS: TNIB) continue to produce a steady stream of good news for investors thanks to positive industry trends. Moreover, Ophthotech Corp (NASDAQ: OPHT), Foundation Medicine Inc (NASDAQ: FMI), Evoke Pharma and Fate Therapeutics Inc (NASDAQ: FATE) are this week's biotech IPOs that will no doubt be watched closely by Wall Street and industry observers in general. With that in mind, consider the following biotech news or recent articles about the industry and the small cap players in it:

• [By John Udovich]

  Yesterday, small cap biotech Acceleron Pharma Inc (NASDAQ: XLRN) rose 9.76%�plus shares are up 183.6% for retail investors since its September IPO, meaning its worth taking a closer look at the stock along with the performance of other biotech IPOs like BIND Therapeutics Inc (NASDAQ: BIND), Ophthotech Corp (NASDAQ: OPHT) and Foundation Medicine Inc (NASDAQ: FMI) which also debuted at the same time.

• [By John Udovich]

  The biotech sector has been pretty exciting this year�with small cap biotech stocks Prana Biotechnology Limited (NASDAQ: PRAN) and TNI BioTech (OTCMKTS: TNIB) having recently produced noteworthy news for investors�while Acceleron Pharma, Inc (NASDAQ: XLRN), Ophthotech (NASDAQ: OPHT) and BIND Therapeutics (NASDAQ: BIND) have just�set term sheets for their upcoming IPOs. Just consider all of the following recent news:

• [By Garrett Cook]

  BIND Therapeutics (NASDAQ: BIND) was down, falling 10.56 percent to $11.52 after the company reported the closing of collaboration deal with Amgen (NASDAQ: AMGN).

Hot Income Companies To Buy For 2014: Norsk Hydro ASA (NHY)

Norsk Hydro ASA is a Norway-based company engaged in a number of activities along the aluminum industry�� value chain. The Company is organized into six segments; the Bauxite & Alumina segment includes the Company�� mining activities, sourcing arrangements and alumina commercial operations; the Primary Metal segment consists of aluminum production, re-melting and casting activities; the Metal Markets segment includes sales and distribution activities relating to products from metal plants, metal sourcing and trading activities; the Rolled Products segment comprises operations of the Company�� rolling mills; the Extruded Products segment focuses on delivering solutions to the building and construction, transportation, and engineered products industries and includes aluminum building systems and precision tubing activities, and the Energy segment is responsible for managing the Company�� captive hydropower production and external power sourcing arrangements to the aluminum business. Advisors' Opinion:

• [By Corinne Gretler]

  Norsk Hydro (NHY) ASA slumped the most in one year after Vale SA sold a stake in the aluminum maker. UniCredit SpA (UCG) and Infineon Technologies AG added at least 1 percent each after posting quarterly profit that beat projections. Henkel AG rose 2.1 percent as third-quarter profit beat analysts��estimates.